ALBERT STONE: Open Payments
NPI 1659852150 · ROOSEVELT, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$246 in 12 payments from 8 companies in 2025. Trend: 2023 $441 · 2024 $467 · 2025 $246
Food & beverage: $246
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $62 |
| Amgen Inc. | 2 | $53 |
| Novartis Pharmaceuticals Corporation | 2 | $40 |
| Genentech USA, Inc. | 1 | $26 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Merck Sharp & Dohme LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $14 |
Products named: BENLYSTA, COSENTYX, EVENITY, Actemra, ENBREL, ORENCIA, VERQUVO, CAPLYTA.
Industry payments across UT — which companies pay providers there.
